Foradil, Formoterol News

FOR IMMEDIATE RELEASE SkyePharma Announces Successful Completion of FlutiformTM EU Clinical Trial Programme LONDON, UK, 2 November, 2009 - SkyePharma PLC today announces that its development and marketing partner Mundipharma International Corporation Limited has successfully completed the final Phase III clinical study for the European development ...

In patients with chronic obstructive pulmonary disease , triple therapy with budesonide/formoterol added to tiotropium significantly improves lung function and reduces severe exacerbations compared to monotherapy with tiotropium, according to a study published in the Oct.

Patients with moderate to severe chronic obstructive pulmonary disease can benefit from triple therapy that includes a long-acting I2-agonist , an inhaled corticosteroid and an anti-muscarinic agent, according to researchers in Germany.

Formoterol is increasingly viewed as the long-acting I22-agonist of choice by pharmaceutical companies wishing to participate in the dynamic inhaled corticosteroid plus long-acting I22-agonist combination therapy segment of the asthma and chronic obstructive pulmonary disease market.

European Respiratory Society Congress 2009, Vienna, Austria, 15 September 2009: Symbicort Turbuhaler Maintenance and Reliever Therapy provides effective symptom control and reduces the risk of severe exacerbations in symptomatic asthma patients on inhaled corticosteroids or combination therapy of ICS and long-acting beta agonists over six months ...

Schering-Plough's Marketing Authorization Application for a fixed-dose combination of mometasone furoate and formoterol fumarate for the treatment of asthma, has been accepted for review by the EMEA.

Main Category: Respiratory / Asthma Also Included In: COPD Article Date: 30 Aug 2009 - 1:00 PDT Contrary to other research findings, patients using the inhaled corticosteroid budesonide to treat Chronic Obstructive Pulmonary Disease are not at increased risk of pneumonia , and the drug is safe to use in these patients, concludes an Article in this ...

Inhaled budesonide is safe to use for chronic obstructive pulmonary disease and does not increase the risk of pneumonia, researchers have found.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Analyst Report ) revealed that the European Medicines Agency will review its candidate for maintenance treatment of asthma in patients 12 years and above and an oral contraceptive for marketing in Europe.

Schering-Plough Corp. said Wednesday the European Medicines Agency is reviewing marketing applications for an asthma treatment and an oral contraceptive.

An author of a new industry-funded study on the safety of a commonly prescribed type of inhaled asthma drug says the findings should be "reassuring" to patients who use them.

NEW illiniengineer asthma Abstract BACKGROUND: Traditionally inhaled treatment for asthma has been considered as preventer and reliever therapy.

Schering-Plough today announced that a New Drug Application for a fixed-dose combination of mometasone furoate and formoterol fumarate has been filed in the United States and accepted for review by the U.S. Food and Drug Administration .

Long-acting I22-agonists , such as salmeterol or formoterol, do not reduce inflammation in patients with chronic persistent asthma, according to a meta-analysis in the July issue of Chest .

There are so many medications out there. We'll tell you what you need to know. Black box warnings are a type of labeling that the Federal Drug Administration requires pharmaceutical companies to use when a drug has possible side effects that are dangerous, rather than just annoying.

Main Category: Respiratory / Asthma Also Included In: Medical Devices / Diagnostics In two recent COPD studies sponsored by DEY LP, PARI's LC Plus nebulizer and PRONEB compressors were used to show that nebulized formoterol fumarate improves pulmonary function.

Mylan Inc. sued Teva Pharmaceutical Industries Ltd. to prevent it from selling a generic version of the Perforomist inhaler for people with chronic bronchitis and emphysema.

SkyePharma PLC today announces that the US Food and Drug Administration has issued a communication in respect of the New Drug Application for its lead development product, FlutiformTM , an investigational treatment for persistent asthma in patients 12 years of age and older.

COPD, or chronic obstructive pulmonary disease, is a respiratory disease affecting thousands of people every year.